Log in

NASDAQ:SGENSeattle Genetics Stock Price, Forecast & News

$116.51
-2.16 (-1.82 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$115.94
Now: $116.51
$119.44
50-Day Range
$95.75
MA: $110.46
$119.97
52-Week Range
$62.90
Now: $116.51
$124.32
Volume753,198 shs
Average Volume1.41 million shs
Market Capitalization$20.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Read More
Seattle Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$916.71 million
Book Value$10.95 per share

Profitability

Net Income$-158,650,000.00

Miscellaneous

Employees1,605
Market Cap$20.07 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.


Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions

How has Seattle Genetics' stock been impacted by COVID-19 (Coronavirus)?

Seattle Genetics' stock was trading at $104.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SGEN shares have increased by 11.5% and is now trading at $116.51. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Seattle Genetics?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 8 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Seattle Genetics.

When is Seattle Genetics' next earnings date?

Seattle Genetics is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for Seattle Genetics.

How were Seattle Genetics' earnings last quarter?

Seattle Genetics, Inc. (NASDAQ:SGEN) posted its earnings results on Thursday, February, 6th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.45) by $0.60. The biotechnology company had revenue of $289.80 million for the quarter, compared to analyst estimates of $219.21 million. Seattle Genetics had a negative return on equity of 13.99% and a negative net margin of 17.31%. The business's revenue was up 66.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.75) earnings per share. View Seattle Genetics' earnings history.

What guidance has Seattle Genetics issued on next quarter's earnings?

Seattle Genetics updated its FY 2020 After-Hours earnings guidance on Thursday, February, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $810-865 million, compared to the consensus revenue estimate of $1.1 billion.

What price target have analysts set for SGEN?

18 Wall Street analysts have issued 1 year price objectives for Seattle Genetics' shares. Their forecasts range from $95.00 to $165.00. On average, they anticipate Seattle Genetics' stock price to reach $123.81 in the next twelve months. This suggests a possible upside of 6.3% from the stock's current price. View analysts' price targets for Seattle Genetics.

What are Wall Street analysts saying about Seattle Genetics stock?

Here are some recent quotes from research analysts about Seattle Genetics stock:
  • 1. According to Zacks Investment Research, "Seattle Genetics reported narrower-than-expected loss in Q1 while revenues beat estimates.Its sole marketed drug, Adcetris, is performing well since its launch. Adcetris’ recent label expansion in frontline stage III/IV Hodgkin lymphoma and in frontline CD30-expressing peripheral T-cell lymphomas (PTCL) bodes well for the company. The company’s collaboration with Takeda for the global development and commercialization of Adcetris also holds promise. However, its heavy dependence solely on Adcetris for growth is a concern. The recent label expansion of Merck’s Keytruda and Bristol-Myers’ Opdivo in the lymphoma indication will increase competition. Though the company has multiple candidates in its pipeline, maximum is in early developmental stages. Any regulatory setback for Adcetris could hurt its sales potential significantly." (5/29/2019)
  • 2. JPMorgan Chase & Co. analysts commented, "Quarter as We maintain our Neutral rating on ZBH shares following 1Q19 results that came in-line with Street expectations (but missed our more bullish forecast) on the top-line with slightly higher expenses than we forecasted. While Hips (+1.7% xFx) and Dental (-0.2% xFx) were bright spots relative to expectations, Knees (+0.7% xFx) continues to remain challenged relative to market growth particularly within the Americas (-0.9% xFx). Importantly volume gains overall were +220bps Y/Y and only negative 30bps Q/Q from a seasonally strong 4Q18. While pricing pressures have not abated, we think the volume gains are notable for ZBH considering the overall pricing environment seen across all large cap orthopedics thus far this season." (4/28/2019)
  • 3. HC Wainwright analysts commented, "We reach a price target of $98 after adjusting new corporate tax rate, cash, and other program updates. The price target is based on a sum-of-parts NPV-DCF ($63.1 HL + $3.6 relapsed sALCL+ $11.2 frontline PTCL + $17.6 platform + $2.6 cash). Key risks to achievement of our target price include trial failures, safety issues, regulatory delays, competition, and dilutive financing. Seattle Genetics Inc. April 26, 2019 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2Seattle Genetics, Inc." (4/26/2019)

Has Seattle Genetics been receiving favorable news coverage?

News stories about SGEN stock have trended very negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Seattle Genetics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutSeattle Genetics.

Who are some of Seattle Genetics' key competitors?

What other stocks do shareholders of Seattle Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seattle Genetics investors own include Immunomedics (IMMU), Gilead Sciences (GILD), Celgene (CELG), AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), Incyte (INCY) and Alexion Pharmaceuticals (ALXN).

Who are Seattle Genetics' key executives?

Seattle Genetics' management team includes the following people:
  • Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 58)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 58)
  • Dr. Vaughn B. Himes, Chief Technology Officer (Age 58)
  • Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 62)
  • Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 51)

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

How do I buy shares of Seattle Genetics?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Seattle Genetics' stock price today?

One share of SGEN stock can currently be purchased for approximately $116.51.

How big of a company is Seattle Genetics?

Seattle Genetics has a market capitalization of $20.07 billion and generates $916.71 million in revenue each year. The biotechnology company earns $-158,650,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Seattle Genetics employs 1,605 workers across the globe. View additional information about Seattle Genetics.

What is Seattle Genetics' official website?

The official website for Seattle Genetics is http://www.seattlegenetics.com/.

How can I contact Seattle Genetics?

Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel